Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma

IJU Case Reports

article

Yohei Ueki¹  Masahiro Matsuki¹  Terufumi Kubo²  Rena Morita²  Yoshihiko Hirohashi²  Syunsuke Sato¹  Ryota Horibe³  Kazuhiko Matsuo⁴  Tomohide Tsukahara²  Takayuki Kanaseki²  Yasunari Takakuwa⁵  Masaaki Satoh⁵  Naoki Itoh¹  Toshihiko Torigoe² 

[1] Department of Urology, NTT-East Corporation Sapporo Medical Center;Department of Pathology, School of Medicine, Sapporo Medical University;Department of Respiratory Medicine, NTT-East Corporation Sapporo Medical Center;Sapporo Clinical Laboratory Inc.;Department of Clinical Pathology, NTT-East Corporation Sapporo Medical Center

关键词: cystitis;    immune checkpoint inhibitor;    immune-related adverse event;    PD-L1.;   

DOI  :  10.1002/iju5.12211

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune-related adverse events. Case presentation The patient was a 78-year-old woman with lung adenocarcinoma who had a partial response to pembrolizumab. During treatment, she complained of pollakiuria and nocturia with painful micturition. Histological analysis revealed infiltration of CD8-positive and/or TIA-1 cytotoxic granule-associated RNA binding protein-positive lymphocytes and programmed death-ligand 1 expression in the urothelium. A diagnosis of immune-related adverse event cystitis was made based on these clinical and pathological findings. The patient’s subjective symptoms and findings on cystoscopy improved dramatically after treatment with prednisolone. Conclusion Immune checkpoint inhibitors-induced cystitis is extremely rare. This report is the first to include an immunohistochemical analysis of the urothelial epithelium in immune-related adverse event cystitis and describes an instructive case.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND